insights_auto
Why is DRUG down 3.15%?
Dive Deeperchevron_right
DRUG:CNSX
Bright Minds Biosciences Inc
CA$74.67
arrow_downward
-3.15%(-2.43) 1D
Oct 13, 4:00:00 PM GMT-4 · CAD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRUG...
Open
CA$77.31
High
CA$77.31
Low
CA$73.97
Mkt. cap
736.55M
Avg. vol.
845.00
Volume
895.00
52-wk high
CA$170.00
52-wk low
CA$68.02
EPS
-CA$2.90
No. of employees
26
Open
CA$77.31
High
CA$77.31
Low
CA$73.97
Mkt. cap
736.55M
Avg. vol.
845.00
Volume
895.00
52-wk high
CA$170.00
52-wk low
CA$68.02
EPS
-CA$2.90
No. of employees
26
News stories
From web sources and news partners
TradingView
·
45 minutes ago
S&P 500 Ends Flat, While Nasdaq Drops As Memory Chipmakers Sell Off — BAC, GME, SPCX, ARM, QCOM In Focus
bloomingbit
·
3 hours ago
New York Stocks Close Lower; Nasdaq Falls 0.15%
Investing.com
·
3 hours ago
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.35%
BigGo Finance
·
1 hour ago
Dow Falls 180 Points as Rising Oil Prices and Weak Tech Weigh on Market
Profile
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
About Bright Minds Biosciences Inc